20 Acorn Park Drive
Tel: (617) 949-4359
About Omega Therapeutics
Omega Therapeutics is a publicly held, development-stage biotechnology company pioneering a new class of DNA-sequence-targeting, mRNA-encoded therapeutics to transform human medicine. The OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics, the mechanism that systematically controls every aspect of an organism’s life from cell genesis, to growth and differentiation. The OMEGA platform has identified thousands of novel DNA-sequence-based epigenomic targets within Insulated Genomic Domains (IGDs), referred to as EpiZips™. IGDs represent the three-dimensional, distinct, and evolutionarily conserved architecture of the genome, and are the fundamental structural and functional units of gene control and cell differentiation. They act as the “control room” of biology. The OMEGA platform examines alterations in IGDs leading to aberrant gene expression, a cause of most disease. It then leverages its database of EpiZips to identify appropriate intervention points within the IGDs and rationally designs biologically engineered, modular, and programmable mRNA-encoded epigenetic medicines, called Omega Epigenomic Controllers™, to target EpiZips for Precision Genomic Control™. With its computation- and data-first approach, Omega Therapeutics is currently advancing a broad pipeline of programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases.
30 articles with Omega Therapeutics
Omega Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
Omega Therapeutics, Inc. announced financial results for the first quarter ended March 31, 2022, and highlighted recent Company progress.
Omega Therapeutics to Unveil Preclinical Data on Epigenomic Programming of MYC with Epigenomic Controllers as a Promising Therapeutic Approach in Non-Small Cell Lung Cancer at the 25th Annual ASGCT Meeting
Omega Therapeutics will present preclinical data on its novel Omega Epigenomic Controller (OEC) to regulate expression of the c-Myc (MYC) oncogene via epigenomic programming in models of NSCLC in a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, taking place in Washington, D.C., May 16-19, 2022.
Omega Therapeutics (NASDAQ: OMGA) (Omega), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform, today announced the appointment of Joshua Reed as Chief Financial Officer, effective May 23, 2022.
Omega Therapeutics Presents Preclinical Data on OTX-2002, First-in-Class Epigenomic Controller, as Potential Treatment for Hepatocellular Carcinoma at the AACR Annual Meeting 2022
Omega Therapeutics (NASDAQ: OMGA) (Omega), will present preclinical data highlighting the potential of its lead Omega Epigenomic Controller™, OTX-2002, to regulate overexpression of the c-Myc (MYC) oncogene in models of hepatocellular carcinoma (HCC) in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022,
Omega Therapeutics, Inc. today announced the appointment of Kevin McManus as Chief Human Resources Officer and Ling Zeng, Esq., as Chief Legal and Administrative Officer.
Omega Therapeutics is harnessing the power of epigenetics in an unprecedented way and engineering programmable epigenetic mRNA therapeutics to transform medicine in the service of patients.
Omega Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Outlines Key Corporate Objectives for 2022
Omega Therapeutics, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2021.
Omega Therapeutics to Present Preclinical Data for OTX-2002 at the American Association for Cancer Research Annual Meeting 2022
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced that it will present preclinical data for OTX-2002.
BioSpace is marking Martin Luther King, Jr. Day by sharing some of our recent coverage about what the life sciences industry is doing to address racial inequality.
Omega Therapeutics, Inc. announced the appointment of Yan Moore, M.D., as Chief Medical Officer.
Omega Therapeutics, Inc. today announced that Mahesh Karande , President and Chief Executive Officer, Roger Sawhney, M.D., Chief Financial Officer, and Thomas McCauley, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference taking place from November 29 – December 2, 2021.
Omega Therapeutics Reports Third Quarter 2021 Financial Results and Outlines Key Corporate Objectives
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced financial results for the third quarter ended September 30, 2021.
Omega Therapeutics, Inc. today announced that Mahesh Karande , President will present at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 8:00 a.m. GMT.
This first-of-its-kind collaboration will leverage the talent and innovation at companies such as Tessera Therapeutics to advance multiple candidates to human proof of concept.
Omega Therapeutics Announces Strategic Research Collaboration with Stanford University School of Medicine
Omega Therapeutics, Inc. today announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers (OECs) to control ocular disease genes associated with inflammation or regeneration of ocular tissues.
Omega Therapeutics, Inc. today announced that Mahesh Karande , President and Chief Executive Officer, will participate in a fireside chat at the Chardan Virtual 5th Annual Genetic Medicines Conference on Monday, October 4, 2021 at 8:30 a.m. ET.
Omega Therapeutics Reports Second Quarter 2021 Financial Results and Outlines Key Corporate Objectives
- Strong Balance Sheet to Fund Pipeline of Omega Epigenomic Controllers™ with $122.4 Million in Cash and Cash Equivelents as of June 30, 2021 and additional $141.1 Million in Gross Proceeds from the Initial Public Offering in the Third Quarter 2021
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), today announced the pricing of its initial public offering of 7,400,000 shares of its common stock at a price to the public of $17.00 per share
7/14/2021More biopharma companies race toward the Nasdaq this week, while a few rake in cash via private funding rounds.
The 2021 IPO stampede continues with five more companies aiming to trade on a stock exchange.